- our experts
- Student Sphere
- Hotel & Travel
Multiple Sclerosis (MS) is a chronic, unpredictable disease that leads to the loss of information exchange in the brain and between the brain and body. MS affects the central nervous system principally spinal cord, optic nerves, and the brain. In Multiple Sclerosis, damaging of insulating covers of nerve cells by demyelinating of these covers in the brain and spinal cord.
In MS, symptoms are like numbness, tingling, dizziness and fatigue, sexual dysfunction, muscle weakness, ataxia, acute or chronic pain, change in sensation, vision problems, tremor, memory problems, and muscle spasms. Signs and symptoms may vary in MS and it depends on the level of the damage to nerve cells.
Multiple Sclerosis is an autoimmune disorder, in which the immune system attacks the myelin sheath which protects the nerve cells leads to communication problems in the body. The main cause behind this is not yet found. But it is believed that it is a result of accumulated genetic and environmental factors. Some cause may be genetic, geographical, infection, and acquired factors as well.
Multiple Sclerosis has no cure. Medication helps to prevent new attacks or to stabilize functioning after an attack.
Market Analysis: The global market for multiple sclerosis (MS) medicines was worth $22.99 billion in 2018, and is expected to reach $28.00 billion by 2026, with a CAGR of 2.5 percent between 2019 and 2026. Multiple sclerosis is a chronic inflammatory disease that causes demyelination, axonal transection, and neurodegeneration in the brain and spinal cord's nerve cells. The global market for multiple sclerosis medications is valued at $27.38 billion in 2021 and is predicted to grow at a CAGR of 6.3 percent to $41.99 billion in 2028. MS affects around 57.8 people per 100,000 in the United States. The prevalence is stated to be 68.8 per 100,000 above the 37th parallel and 35.5 per 100,000 below it. Scientists are still working hard to develop new and improved treatments for MS. By 2028, the global market for multiple sclerosis drugs will be valued $ 42.46 billion, with a 6.3 percent compound annual growth rate.
ALSO READ Neurology Neurosurgery Neuroscience Neuropsychiatry Pain Disorder and Management Central Nervous System Pediatric Neurology Neuro-Oncology and Brain Tumors Neurophysiology Neuroimmunology Neuropathology Neuroimaging Neurodegenerative disease and Neurodegeneration Neurological Disorders Sleep Disorder Stroke Movement Disorders Parkinsons Disease Epilepsy Multiple Sclerosis Alzheimers Disease and Dementia Neuromuscular Disease Case Studies and Clinical Trials Novel Treatment Strategies Speech Disorders Demyelinating Disorders Cerebrovascular Disorders Autoimmune and Inflammatory Disorders Neuropathy Headache and Facial Pain Diagnosis and Screening of Neurological Disorders Neuropharmacology and Neurochemistry Stem Cells and Neuroregeneration Cognitive Neuroscience Motor System Disorders Behavioral Neurology Computational Neuroscience Neurogenetics Spinal Neurosurgery Pediatric Neurosurgery Stereotactic and Functional Neurosurgery Neurovascular Surgery Intraoperative Neurophysiology Peripheral Nerve Surgery Robotics in Neurosurgery Latest advancement in Brain Surgery Skull Base Surgery Trauma and Critical Care
Neurology Conferences USA Neurology Conferences 2022 Neurology Conferences 2022 USA CNS Conferences Dementia Conferences Spinal Disorders Conferences Headache Conferences Sleep Disorders Conferences Child Psychology Conferences Seizures Conferences Stroke Conferences Brain Cancer Conferences Neurology Conferences 2022 Europe Neurology Conferences 2022 Euro Neurology Conferences